2020
COVID-19 therapeutic options for patients with kidney disease
Izzedine H, Jhaveri KD, Perazella MA. COVID-19 therapeutic options for patients with kidney disease. Kidney International 2020, 97: 1297-1298. PMID: 32317113, PMCID: PMC7271263, DOI: 10.1016/j.kint.2020.03.015.Peer-Reviewed Original Research
2004
Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease
Perazella M, Mosenkis A, Berns J. Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars In Dialysis 2004, 17: 411-416. PMID: 15461751, DOI: 10.1111/j.0894-0959.2004.17351.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngina, UnstableDiabetes Mellitus, Type 2Diabetic NephropathiesDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFollow-Up StudiesHeparin, Low-Molecular-WeightHumansKidney Failure, ChronicMalePlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexRisk AssessmentTreatment OutcomeConceptsLow molecular weight heparinIIb/IIIa inhibitorsChronic kidney diseaseAcute coronary syndromeEnd-stage renal diseaseMolecular weight heparinWeight heparinKidney diseaseGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsSafety of LMWHLarge prospective trialsMajor clinical trialsCardiac causesCoronary syndromeAppropriate dosingProspective trialRenal diseaseKidney functionAggressive interventionClinical benefitClinical trialsPatientsSignificant impairmentDisease
2000
Trimethoprim-Induced Hyperkalaemia
Perazella M. Trimethoprim-Induced Hyperkalaemia. Drug Safety 2000, 22: 227-236. PMID: 10738846, DOI: 10.2165/00002018-200022030-00006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnti-Infective Agents, UrinaryDose-Response Relationship, DrugHumansHyperkalemiaKidneyRisk FactorsTrimethoprimConceptsRenal potassium excretionPotassium excretionHigh urinary flow ratesPotassium homeostasisManagement of hyperkalaemiaGlomerular filtration ratePotassium-sparing diuretic amilorideUrinary flow rateRecognition of patientsDistal nephron cellsTrimethoprim therapyRenal impairmentCommon complicationLoop diureticsEpithelial sodium channelIntravenous fluidsVolume repletionAdverse reactionsFiltration rateRisk factorsStandard dosageAntikaliuretic effectHyperkalaemiaIsotonic fluidsDistal nephron
1996
Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose.
Perazella M, Mahnensmith R. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose. Clinical Nephrology 1996, 46: 187-92. PMID: 8879854.Peer-Reviewed Original ResearchConceptsTrimethoprim-sulfamethoxazole therapyStandard doseDevelopment of hyperkalemiaTrimethoprim-sulfamethoxazole useMild renal insufficiencyProspective surveillance studyPotassium-sparing diuretic amilorideRenal potassium excretionPneumocystis carinii pneumoniaLethal adverse reactionHandful of casesRenal insufficiencyElderly patientsPotassium excretionSevere hyperkalemiaImportant complicationAIDS patientsCarinii pneumoniaTrimethoprim-sulfamethoxazoleAdverse reactionsInduced hyperkalemiaPotassium disordersHyperkalemiaSurveillance studyPatients